Ascendis Health (JSE:ASC) EBIT : R-239 Mil (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Ascendis Health EBIT?

Ascendis Health's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was R-121 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was R-239 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ascendis Health's annualized ROC % for the quarter that ended in Jun. 2023 was -19.69%. Ascendis Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -46.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ascendis Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -55.05%.

Ascendis Health EBIT Historical Data

The historical data trend for Ascendis Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Health EBIT Chart

Ascendis Health Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

-1,251.38

-930.66

-508.28

-358.80

-239.35

Ascendis Health Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT	Get a 7-Day Free Trial															-314.66	-256.61	-102.19	-118.36	-120.99

Competitive Comparison of Ascendis Health's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ascendis Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Health's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ascendis Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ascendis Health's EV-to-EBIT falls into.

Ascendis Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was R-239 Mil.

Ascendis Health (JSE:ASC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ascendis Health's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-151.368 * ( 1 - 2.15% )	/	( (892.947	+	611.761)	/ 2 )
=	-148.113588	/	752.354
=	-19.69 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1396.254	-	378.249	-	( 125.058	-	max(0, 541.251	-	891.965	+	125.058	))
=	892.947

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	970.711	-	254.872	-	( 104.078	-	max(0, 380.409	-	747.906	+	104.078	))
=	611.761

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Ascendis Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-241.974	/	( ( (343.76 + max(295.795, 0))	+	(137.054 + max(275.415, 0)) )	/	2 )
=	-241.974	/	( ( 639.555	+	412.469 )	/	2 )
=	-241.974	/	526.012
=	-46.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(307.863	+	439.531	+	19.513)	-	(378.249	+	0	+	92.863)
=	295.795

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(224.322	+	365.938	+	34.333)	-	(254.872	+	0	+	94.306)
=	275.415

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ascendis Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-239.345	/	434.774
	=	-55.05 %

Ascendis Health EBIT Related Terms

Thank you for viewing the detailed overview of Ascendis Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Health (JSE:ASC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ascendis Health Ltd (JSE:ASC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Carey Street, Wynberg, Sandton, GT, ZAF, 2090

Website

https://www.ascendishealth.com

Ascendis Health is a drug manufacturer that produces and distributes health products for the human, animal, and plant markets. It has a portfolio of brands and products and owns recognized trademarks in the pharmaceutical and consumer health markets. Ascendis Health has five operating segments: consumer health, pharma, medical, animal health, and biosciences. The pharma division is the contributor to revenue and is further divided into Pharma Africa, Remedica, and Farmalider. Pharma includes generic manufacturing and distribution and over-the-counter medicine manufacturing and distribution. The company's revenue is split between South Africa and Europe and is diversified across currencies, markets, sales channels, and customer groups.